# JUN

Source: https://onco.cc/targets/jun/  
OnCo record `jun` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JUN (Transcription factor Jun) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer and Melanoma.

## Summary

Transcription factor that recognises and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3'. Heterodimerises with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional activity. Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signalling pathway.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Irbesartan. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 1.00, affected pathway 0.71, animal model 0.33, somatic mutation 0.96).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: Jun proto-oncogene, AP-1 transcription factor subunit; Transcription factor Jun; c-Jun; AP-1
- Tags: cancer-genes-wave
- Symbol: JUN
- Class: transcription
- Biology: Transcription factor that recognises and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3'. Heterodimerises with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional activity. Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signalling pathway. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signalling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells. Location: Nucleus (UniProt). Locus 1p32.1 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.54 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease; Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Melanoma: Open Targets association 0.56 with melanoma (MONDO_0005105)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:6204: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6204
- UniProt P05412: https://www.uniprot.org/uniprotkb/P05412/entry
- NCBI Gene 3725: https://www.ncbi.nlm.nih.gov/gene/3725
- Ensembl ENSG00000177606: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177606

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/jun.json